Cargando…
Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180777/ https://www.ncbi.nlm.nih.gov/pubmed/21961001 http://dx.doi.org/10.1155/2012/540791 |
_version_ | 1782212694114304000 |
---|---|
author | Amini, Afshin Masoumi Moghaddam, Samar Morris, David L. Pourgholami, Mohammad H. |
author_facet | Amini, Afshin Masoumi Moghaddam, Samar Morris, David L. Pourgholami, Mohammad H. |
author_sort | Amini, Afshin |
collection | PubMed |
description | Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies. |
format | Online Article Text |
id | pubmed-3180777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31807772011-09-29 Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application Amini, Afshin Masoumi Moghaddam, Samar Morris, David L. Pourgholami, Mohammad H. J Oncol Review Article Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies. Hindawi Publishing Corporation 2012 2011-09-26 /pmc/articles/PMC3180777/ /pubmed/21961001 http://dx.doi.org/10.1155/2012/540791 Text en Copyright © 2012 Afshin Amini et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Amini, Afshin Masoumi Moghaddam, Samar Morris, David L. Pourgholami, Mohammad H. Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application |
title | Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application |
title_full | Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application |
title_fullStr | Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application |
title_full_unstemmed | Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application |
title_short | Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application |
title_sort | utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180777/ https://www.ncbi.nlm.nih.gov/pubmed/21961001 http://dx.doi.org/10.1155/2012/540791 |
work_keys_str_mv | AT aminiafshin utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication AT masoumimoghaddamsamar utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication AT morrisdavidl utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication AT pourgholamimohammadh utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication |